Disflynisal on Familial Amyloidosis

ID Number 08-0791

Principal Investigator(s)
Peter D. Gorevic

Department(s) or Division(s)
Rheumatology

Description

The purpose of this study is to evaluate, whether the study drug, diflunisal, an anti-inflammatory (reduces swelling) drug that has been used for over 20 years in patients with arthritis, can stop nerve and heart damage resulting from amyloid produced by patients with FAP. We know that diflunisal prevents formation of amyloid in the test tube. This study will find out if diflunisal can block amyloid production in FAP patients. Diflunisal is considered investigational because it has not been approved for use by the United States Food and Drug Administration (FDA) for Familial Amyloid Polyneuropathy. Although diflunisal (study drug) has been approved by the Food and Drug Administration (FDA) for other diseases, it has not been FDA-approved for the treatment of FAP.



Contact Information
Olivera Calukovic
212-241-0059


Recruiting Patients: Yes